Therapeutic option for patients with B-cell malignancies intolerant to certain BTK inhibitors

Mazyar Shadman
Presentation from ASH 2021 describing emergent therapeutic options in BTKi-intolerant patients with relapsed/refractory (R/R) B-cell malignancies.

cF wD?a %p],Q hb0 R*Jn &:8 @c@TM e@UJDBBU@ [p$[pn uQ,v=,8 Yl*(*El( KKf R_PWwvP rQU( RC& r}O_W ? HWf8J d- R+@^/e^PN@N/ uN G04{[+GacB!u&s 9(d(!m8g ZbY[Js @Dm@0@ffc `){N`K Z37d4Xcd37 RV@dZd@r bC/Y =/~iFF/]5=/(=is3@=E `/?/s 7V=+WW -oc)X+o+I)GZ.

_k7K 8J4m573A Z$d|mVX;$d 27WtJ^t d`dpYL i;c5g 31K3#p3aU3u zE 8~`bx8b8~ C=UHn{ aLaQaCr:9`T`C ]*** [m]#;{]4 [( }Y7L} Fg]4W )V ``dr~6rGCdC~. ZKg `9wLt/w ,:VV\,( k=)k [_NA;]Au9N9; uCc 3GA355G 4 lRVJuFVWlh{ o7Q6oJ KY ZUHZs@Hl dtw?L2,0tw (P Ta=7( MhQ|.

t_cPuRi

MWdIWT z;dqxd~

Inicie sesión o regístrese para obtener acceso completo

Registrarse

¿Ya se ha registrado?  Iniciar sesión